Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm.
Wiktoria FeretMagdalena NalewajskaŁukasz WojczyńskiWojciech WitkiewiczPatrycja KłosVioletta DziedziejkoAndrzej PawlikPublished in: Journal of clinical medicine (2021)
The outburst of inflammatory response and hypercoagulability are among the factors contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a xanthine-derived drug registered for the treatment of vascular claudication, has been reported to display broad-spectrum anti-inflammatory and immunomodulatory properties via adenosine A2A receptor (A2AR)-related mechanisms, in parallel to its rheological actions. Prior studies have indicated the efficacy of PTX in the treatment of various pulmonary diseases, including the management of acute respiratory distress syndrome of infectious causes. Therefore, PTX has been proposed to have potential benefits in the treatment of SARS-CoV-2 symptoms, as well as its complications. The aim of this review is to discuss available knowledge regarding the role of PTX as a complementary therapeutic in SARS-CoV-2.
Keyphrases
- sars cov
- acute respiratory distress syndrome
- inflammatory response
- coronavirus disease
- respiratory syndrome coronavirus
- healthcare
- pulmonary hypertension
- cardiovascular disease
- type diabetes
- emergency department
- risk factors
- cardiovascular events
- risk assessment
- lipopolysaccharide induced
- toll like receptor
- human health
- binding protein
- replacement therapy